John Eikelboom, MD, of McMaster University discusses the 3 arms of the COMPASS trial and explains the need for it to end earlier than anticipated.
John Eikelboom, MD, of McMaster University discusses the 3 arms of the COMPASS trial and explains the need for it to end earlier than anticipated.
Transcript (slightly modified)
What were the basic findings of the COMPASS trial and why was it stopped early?
The COMPASS trial was a 3-arm study and it tested the combination of rivaroxaban—about 2.5 mg twice a day—and aspirin; rivaroxaban alone; and aspirin alone. The winning arm in this study was the combination, which was superior to aspirin. The Data Safety Monitoring Board stopped the trial early because they found that the difference in treatment effects and the event rates were so different at the interim analysis, that it exceeded the stopping rule.
The results to summarize: the combination, compared with aspirin, reduced the primary outcome of cardiovascular death, stroke, or myocardial infarction by 24% with a consistent effect on the components of that outcome. It also reduced the outcome of mortality—so, an 18% reduction in mortality. There was a price to pay, and the price to pay was an increase in bleeding and the hazard ratio was 1.7, so there was clearly an increase in bleeding. But, reassuringly, there was no excess of the most severe bleeds.
When we look at the net benefit, the ultimate measure of net benefit is actually mortality and there was a reduction in mortality, as I’ve mentioned. There was also a reduction in a pre-specified net benefit analysis that included the primary outcome and the severe bleeds.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More